AI-Augmented FSP for clinical biometrics
Astraea offers an AI-Augmented FSP that operates the platform inside a validated environment until the customer’s team owns the workflow.
tryastraea.comCrawled Oct 15, 2026
Astraea offers an AI-Augmented FSP that operates the platform inside a validated environment until the customer’s team owns the workflow.
Full-service biostatistics and programming from protocol design through NDA, BLA, and IND submissions, inspection-ready deliverables, FDA and EMA aligned.
The company provides clinical trial automation software for SAPs, SDTM/ADaM, TLFs, Define-XML, QC, and submission documents within a customer's own environment.
Automate SDTM and ADaM mapping, Define-XML, aCRFs, and TLF generation with human review and audit-ready traceability.
Astraea offers sponsor-run software that automates post-protocol work through submission, with statisticians approving every output.
Astraea vs. Koneksa Lodestar: compare workflow scope, early-access availability, benchmark evidence, and Astraea's in-environment deployment model.
The page compares cloud clinical data software with sponsor-run automation deployed inside the customer’s environment, from SAP through submission.
Compare Astraea with TriClick software and, separately, Hill Research's project-based biostatistics and FSP services using current first-party evidence.
Sponsor-run clinical trial automation software installed inside customer environments, built by biostatisticians, clinical programmers, and sponsor-side leaders.
Astraea compresses biometrics and submission timelines.
Astraea automates SAPs, SDTM/ADaM, TLFs, Define-XML, QC, and FDA submission documents inside the customer’s environment. The software is sponsor-run, not a CRO.
The page explains how Astraea collects, uses, and safeguards personal information across its website and clinical trial automation platform.
The page describes the terms governing use of the Astraea website, platform, and related services, including acceptable use, customer data, compliance, and liability.
Astraea targets automation of clinical trial biometrics for Phase II/III sponsors. YC Tier List rates it B-tier among Spring 2026 Y Combinator companies.
Astraea (YC P26) has automated the clinical trial biometrics pipeline. The company helps pharma teams turn raw clinical data into FDA-ready packages in days.
Astraea joins Y Combinator’s Spring 2026 batch, co-founder Joshua Wang announces. The company is working to automate the biometrics pipeline for pharma teams.
Astraea launches on Y Combinator with an agentic platform that automates clinical trial data analysis and statistical programming. The platform generates CDISC-compliant datasets, TFLs, and FDA-ready outputs.